INS and Hepatic fibrosis: Recent studies—2426 patients with HCV, 42% of whom had liver fibrosis stage F0-F2 and 58% of whom had liver fibrosis stage F3–F4—have shown that effective HCV treatment with DAA was associated with significant reductions in HOMA-insulin resistance and HOMA-β-cell function, an increase in HOMA-insulin sensitivity, and a reduction of the prevalence of diabetes in this group of patients [9].